This is the authors' abstract. We don't add key points for this paper.
Polymersomes have been proposed as a platform for drug delivery systems since late 90s. They are exploited to deliver hydrophilic and/or hydrophobic therapeutic and diagnostic agents. The relatively robust membrane, the colloidal stability, along with a significant biocompatibility and easy ligands conjugation methods make polymersomes primary candidates for therapeutic drugs delivery in cancer clinical treatments. In addition, they represent an optimal choice as imaging tools in noninvasive diagnostic. As a result, polymersomes have been proposed and widely studied for anticancer treatments. However, there are not sufficient clinic translation data of human studies yet. In this critical review, we will discuss such topics, focusing on the self-assembly of membrane-forming copolymers, on their tunable physicochemical properties and on the consequential applications of these biocompatible polymersomes in drug delivery and cancer therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: